Medicare open enrollment has begun, giving beneficiaries a window to review coverage and compare options for 2027. This year’s shopping season comes with unusually important changes already on the horizon, including new prescription drug rules, an increase in out-of-pocket limits, and the end of a temporary premium subsidy that has been helping offset costs for some people.
For many households, the biggest question is not simply which plan has the lowest monthly premium. The more important issue is how a plan treats commonly used medicines, including drugs for diabetes and obesity, and whether coverage changes could shift total yearly spending.
What is changing
According to AP’s reporting, Medicare’s annual open enrollment runs through Dec. 7, and changes selected during this period take effect Jan. 1. The most notable updates for 2027 include a higher annual out-of-pocket cap for Part D prescription drugs, a higher standard deductible, the end of a temporary Part D premium subsidy, and newly negotiated Medicare drug prices for a group of medicines, including Ozempic, Rybelsus and Wegovy.
AP reported that the Part D annual out-of-pocket maximum will rise to $2,400 in 2027 from $2,100 in 2026, while the standard deductible will increase from $615 to $700. The temporary federal subsidy that has been helping limit some premium costs is scheduled to end at the close of the year.
These changes do not mean every beneficiary will pay more for every drug. But they do mean that the cost structure of Part D plans is changing again, and people who use regular prescriptions may want to look closely at how their current plan handles the drugs they take most often.
Why this matters for everyday care
Prescription coverage can play a major role in chronic disease management. Medicines used for diabetes and weight control are often part of broader treatment plans that also address blood pressure, cholesterol and overall cardiovascular risk. The National Institute of Diabetes and Digestive and Kidney Diseases notes that people with diabetes can lower their risk of heart disease and stroke by managing blood glucose, staying active, making healthy food choices, aiming for a healthy weight and treating other health conditions that raise risk.
The U.S. Food and Drug Administration has also approved Wegovy, a semaglutide medicine, to reduce the risk of cardiovascular death, heart attack and stroke in adults with cardiovascular disease and either obesity or overweight. That does not mean the drug is a substitute for other preventive care, but it does show why access and affordability matter for some patients and clinicians discussing long-term treatment.
Medicare’s drug-price negotiations could affect what enrollees pay out of pocket for certain medicines, including some that are widely prescribed and often expensive. Lower prices can make treatment easier to sustain for some people, though the size of any savings will vary by plan and by individual coverage details.
What the evidence actually shows
Evidence from regulators and medical agencies supports a careful reading of these policy changes. The FDA says semaglutide’s approved cardiovascular indication is based on evidence showing fewer major cardiovascular events in eligible adults, along with standard care and lifestyle counseling. That supports use in specific patients, but it does not prove that every person taking a GLP-1 medicine will see the same benefit or that the drug alone is responsible for improved health outcomes.
At a broader level, NIH materials emphasize that diabetes care, blood pressure control, lipid management and healthy weight are all connected. For people at elevated cardiovascular risk, that means medication access can be part of a larger prevention strategy rather than a stand-alone solution.
AP’s reporting also notes that the 2027 changes arrive alongside broader pressure on household budgets and the annual decision-making that comes with Medicare enrollment. For many enrollees, the practical challenge is not understanding the policy headlines; it is figuring out which plan still covers the medicines and providers they rely on at a price they can manage.
What remains uncertain
It is too early to know how much individual beneficiaries will actually save, or whether plan changes will offset higher deductibles and the loss of temporary subsidies. Medicare Advantage plans can also change benefits, provider networks and cost-sharing from year to year, which can create additional disruption beyond the Part D changes.
Another unknown is how much the new negotiated prices will matter at the pharmacy counter for different people. A drug can have a lower negotiated price and still feel expensive if a person’s plan applies a high deductible, a preferred-brand tier, prior authorization rules or other utilization controls.
There is also a difference between a policy taking effect and a person feeling its impact immediately. Some changes will show up at the start of 2027, while others may be felt gradually as plans update formularies, premiums and pharmacy billing.
What beneficiaries may want to review now
For people with Medicare who take regular prescriptions, the open enrollment window is a good time to compare more than just monthly premiums. It can help to check whether a plan:
- covers each regular medication on its formulary,
- uses a preferred pharmacy network,
- has a deductible that applies before coverage begins,
- sets different copays for brand-name and specialty drugs, and
- limits access through prior authorization or step therapy.
Those details matter most for medicines that are expensive or used continuously. A plan with a lower premium may still cost more over the year if it has a higher deductible or less favorable drug coverage.
People who take medicines for diabetes, cholesterol, blood pressure or weight-related conditions should also check whether a new plan changes the out-of-pocket price of refills, because even modest monthly increases can add up over a year. If a medication suddenly becomes harder to afford, a clinician or pharmacist may be able to discuss whether a covered alternative exists, but any medication change should be based on medical guidance rather than cost alone.
When to seek care
Medication access problems are usually not an emergency, but symptoms such as chest pain, shortness of breath, one-sided weakness, trouble speaking or sudden vision changes require urgent medical attention. Those symptoms can signal a heart attack or stroke and should not wait for an enrollment decision or a plan review.
For everyone else, the main takeaway is straightforward: this Medicare season is not only about choosing a plan for 2026. It is also about preparing for 2027, when several prescription-drug changes could reshape costs for many beneficiaries and may affect how people manage long-term conditions.
